Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ChemoMetec ASOCSE:CHEMM +0.19%98 EV-to-EBIT is 30.24 as of Aug. 07, 2026, which is 41% below its 10-year median of 51.05. GuruFocus rates OCSE:CHEMM with a GF Score™ of 98/100 and a GF Value™ of kr529.93 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 469 Medical Devices & Instruments companies, ChemoMetec AS ranks worse than 71.22% on this metric.
The historical rank and industry rank for ChemoMetec AS's EV-to-EBIT or its related term are showing as below:
OCSE:CHEMM'
s EV-to-EBIT Range Over the Past 10 Years
Min: 18.39 Med: 51.05 Max: 180.01
Current: 30.23
During the past 13 years, the highest EV-to-EBIT of ChemoMetec AS was 180.01. The lowest was 18.39. And the median was 51.05.
OCSE:CHEMM's EV-to-EBIT is ranked worse than 71.22% of 469
companies
in the Medical Devices & Instruments industry
Industry Median: 18.89
vs OCSE:CHEMM: 30.23
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
ChemoMetec AS's Enterprise Value for the quarter that ended in Dec. 2025 was kr11,694.4 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. ChemoMetec AS's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was kr229.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ChemoMetec AS EV-to-EBIT Related Terms
ChemoMetec AS EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for ChemoMetec AS's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OCSE:CHEMM vs ABT, SYK, MDT: EV-to-EBIT Comparison
For the Medical Devices subindustry, ChemoMetec AS's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ChemoMetec AS EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ChemoMetec AS's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where ChemoMetec AS's EV-to-EBIT falls into.
ChemoMetec AS's current Enterprise Value is kr6,952.6 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. ChemoMetec AS's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was kr229.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ChemoMetec AS (OCSE:CHEMM) has a EV-to-EBIT of 30.24 as of Aug. 07, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on ChemoMetec AS and its competitors. This is 41% below median its historical median of 51.05. Over the past decade, ChemoMetec AS's EV-to-EBIT has ranged from 18.39 to 180.01. According to the industry distribution chart, ChemoMetec AS ranks #334 out of 469 companies in the Medical Devices & Instruments industry, placing it in the top 71.2%.
Is ChemoMetec AS's EV-to-EBIT too high?
ChemoMetec AS's current EV-to-EBIT of 30.24 is 41% below median its 10-year median of 51.05. Over the past 10 years, this metric has ranged from a low of 18.39 to a high of 180.01. The Medical Devices & Instruments industry median EV-to-EBIT is 18.89. ChemoMetec AS's value of 30.24 is 60.1% above this industry median. Based on the distribution chart, ChemoMetec AS ranks #334 out of 469 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, ChemoMetec AS has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ChemoMetec AS's EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, ChemoMetec AS ranks #334 out of 469 companies for EV-to-EBIT. This places ChemoMetec AS in the lower half of its industry. The industry median EV-to-EBIT is 18.89. ChemoMetec AS's value of 30.24 is 60.1% above this benchmark. Historically, ChemoMetec AS's own EV-to-EBIT has ranged from 18.39 to 180.01 over the past decade. While the company's 10-year median is 51.05 vs. the industry median of 18.89, ChemoMetec AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.89, based on 469 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ChemoMetec AS's current EV-to-EBIT of 30.24 is 60.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on ChemoMetec AS and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ChemoMetec AS's current EV-to-EBIT is 30.24, which is 41% below median its own 10-year median of 51.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ChemoMetec AS stock overvalued right now?
Based on GuruFocus' analysis, ChemoMetec AS (OCSE:CHEMM) is currently considered Modestly Undervalued. The stock's GF Value™ is kr529.93, compared to a current price of kr415.00 — trading 21.7% below its estimated fair value. The current EV-to-EBIT is 30.24, which is 41% below median its 10-year median of 51.05 and 60.1% above the Medical Devices & Instruments industry median of 18.89. ChemoMetec AS's overall GF Score™ is 98/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For ChemoMetec AS (OCSE:CHEMM), the current EV-to-EBIT is 30.24 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ChemoMetec AS (OCSE:CHEMM) Overvalued in 2026?
Based on GuruFocus' analysis, ChemoMetec AS stock appears to be undervalued.
The current stock price of kr415.00 is trading 21.7% below its estimated GF Value™ of kr529.93.
GuruFocus considers ChemoMetec AS to be Modestly Undervalued.
Key valuation signals for OCSE:CHEMM:
EV-to-EBIT: 30.24 (41% below median its 10-year median of 51.05)
GF Value™: kr529.93 vs. price of kr415.00 (21.7% below fair value)
Industry Position: 60.1% above the Medical Devices & Instruments median (#334 of 469)
No single metric tells the full story. See the OCSE:CHEMM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ChemoMetec AS specializes in designing, developing, and producing instruments using patented technology in cell counting and evaluation. It is engaged in the manufacturing and marketing of analytical instruments used for quantitative analysis of cells in liquids. Its applications include Cell Analysis and counting of Mammalian Cells, Yeast Cells, and Sperm Cells. It provides platforms for the determination of viability and cell count of yeast, veterinary semen, mammalian cells, and somatic cells as well as image analysis. It has four segments instruments; consumables; services and others, and the majority of its revenue is generated from the Consumable segment.
98GF Score
Get the complete analysis for OCSE:CHEMM
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:CHEMM has been successfully added to your 
